StockNote
DAN
Danapha Pharmaceutical Joint Stock Company (DAN) was established on April 1, 1965 with the predecessor of Central Central Pharmaceutical Factory (K25). In 2007, the Company officially operated in the form of a joint stock company. DAN is primarily involved in the manufacture, research and sales of pharmaceuticals. The company is one of the top 10 most prestigious pharmaceutical manufacturers in Vietnam today. DAN's products are distributed mainly through the ETC channel, through central health facilities and the local Department of Health. In addition, the company's products are also exported to Eastern European countries such as Russia, Ukraine, Kazakhstan, Uzbekistan,... and Laos. One of the company's typical products is Golden Star High. On December 22, 2021, DAN was officially traded on the UPCoM market.
DAN currently has a market capitalization of roughly VND 693 billion, placing it in the small-cap group on the Vietnamese stock market. Its current P/E of 5,3x is 54% below its own 6-year average (11,4x), suggesting the stock is trading cheaper than its historical norm. P/B stands at 0,8x, 26% below its multi-year average of 1x. Return on equity (ROE) is at 15,5%, up from 10,7% the year before. Its debt-to-equity ratio of 0,8x is moderate, reflecting a balanced capital structure. In 2025, revenue grew 15% year-on-year while after-tax profit grew 23%.
This note is generated automatically from the stock's real financial data, for reference only — not investment advice.
Revenue & Profit
Unit: VND billion. Growth (%) vs. previous period.
Market Cap
Unit: VND billion. Year-end values; current year uses latest session.
Debt / Equity
Unit: x. Financial debt over shareholders' equity.
Data aggregated from cafef.vn and VNDirect, for reference only, not investment advice.